In a genetic population health study, the test will help identify people most at risk for progressing to cirrhosis and liver-related outcomes, Renown Institute said.
The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.